Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2023 annual report, the company carries out wholesale and retail trade in pharmaceutical products.
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | CAGR |
|---|---|---|---|---|---|---|
| Total Revenue | 3,728 | 4,622 | 7,695 | 12,522 | 10,961 | +30.9% |
| Total COGS | 1,575 | 2,057 | 3,440 | 5,550 | 4,135 | +27.3% |
| Gross Profit | 2,153 | 2,565 | 4,255 | 6,972 | 6,826 | +33.4% |
| Gross Margin | 57.7% | 55.5% | 55.3% | 55.7% | 62.3% | |
| 905 | 1,416 | 1,880 | 2,388 | 4,047 | +45.4% | |
| EBITDA | 1,248 | 1,150 | 2,375 | 4,584 | 2,779 | +22.2% |
| EBITDA Margin | 33.5% | 24.9% | 30.9% | 36.6% | 25.4% | |
| Total D&A | 1 | 5 | 8 | 15 | 27 | +159.6% |
| EBIT / Operating Income | 1,247 | 1,145 | 2,367 | 4,569 | 2,752 | +21.9% |
| Total Interest Expense | 2 | 8 | 27 | 40 | 90 | +163.5% |
| 24 | 120 | 667 | 821 | 145 | nmf | |
| Profit Before Tax | 1,222 | 1,017 | 3,006 | 5,350 | 2,807 | +23.1% |
| Total Income Tax | 31 | 82 | 157 | 244 | 210 | +61.7% |
| Net Profit / (Loss) | 1,191 | 807 | 2,805 | 4,715 | 2,560 | +21.1% |
| Net Margin | 32.0% | 17.5% | 36.5% | 37.7% | 23.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →